Sign In
Buy RETA
$172.36
+0 (+0%)
At Close: Dec 22, 2023
New York, New York--(Newsfile Corp. - October 30, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata"
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and August 7,
Reata Announces Publication of Results From Pivotal Moxie Trial of Omaveloxolone in Patients with Friedreich's Ataxia
07:00pm, Monday, 26'th Oct 2020
PLANO, Texas, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced th
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Reata Pharmaceuticals, Inc. (N
LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc.
Pomerantz Law Firm Announces the Filing of a Class Action against Reata Pharmaceuticals, Inc. and Certain Officers - RETA
11:19pm, Thursday, 15'th Oct 2020
NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) and certain of
PLANO, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (“Reata” or “the Company” or “we”) announced today the upcoming presentation of K ID NEYCODE: A Genetic Testing
Reata Pharmaceuticals, Inc. (RETA) Down 6.2% Since Last Earnings Report: Can It Rebound?
11:30am, Wednesday, 09'th Sep 2020
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago.
PLANO, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced
Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts
11:26am, Tuesday, 11'th Aug 2020
Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.
Reata Slips On Update And Other News: The Good, Bad And Ugly Of Biopharma
09:16am, Tuesday, 11'th Aug 2020
Reata Slips On Update And Other News: The Good, Bad And Ugly Of Biopharma
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q2 2020 Results - Earnings Call Transcript
01:05pm, Monday, 10'th Aug 2020
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q2 2020 Results - Earnings Call Transcript
Why Reata Pharmaceuticals Stock Is Plunging Today
12:26pm, Monday, 10'th Aug 2020
The clinical-stage drug company may not be able to file for FDA approval of a top candidate as soon as expected.
Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates
08:05am, Monday, 10'th Aug 2020
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 8.56% and 111.93%, respectively, for the quarter ended June 2020.
